El CRAI romandrà tancat del 24 de desembre de 2025 al 6 de gener de 2026. La validació de documents es reprendrà a partir del 7 de gener de 2026.
El CRAI permanecerá cerrado del 24 de diciembre de 2025 al 6 de enero de 2026. La validación de documentos se reanudará a partir del 7 de enero de 2026.
From 2025-12-24 to 2026-01-06, the CRAI remain closed and the documents will be validated from 2026-01-07.
 
Miniatura

Fitxers

tinto2015_2031.pdf (475.38 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2015-12-04

Llicència de publicació

cc by (c) Tinto et al., 2015
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/69257

Assessment of the safety of antimalarial drug use during early pregnancy (ASAP): protocol for a multicenter prospective cohort study in Burkina Faso, Kenya and Mozambique

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

http://dx.doi.org/10.1186/s12978-015-0101-0

Resum

BACKGROUND: A major unresolved safety concern for malaria case management is the use of artemisinin combination therapies (ACTs) in the first trimester of pregnancy. There is a need for human data to inform policy makers and treatment guidelines on the safety of artemisinin combination therapies (ACT) when used during early pregnancy. METHODS: The overall goal of this paper is to describe the methods and implementation of a study aimed at developing surveillance systems for identifying exposures to antimalarials during early pregnancy and for monitoring pregnancy outcomes using health and demographic surveillance platforms. This was a multi-center prospective observational cohort study involving women at health and demographic surveillance sites in three countries in Africa: Burkina Faso, Kenya and Mozambique [(ClinicalTrials.gov Identifier: NCT01232530)]. The study was designed to identify pregnant women with artemisinin exposure in the first trimester and compare them to: 1) pregnant women without malaria, 2) pregnant women treated for malaria, but exposed to other antimalarials, and 3) pregnant women with malaria and treated with artemisinins in the 2nd or 3rd trimesters from the same settings. Pregnant women were recruited through community-based surveys and attendance at health facilities, including antenatal care clinics and followed until delivery. Data from the three sites will be pooled for analysis at the end of the study. Results are forthcoming. DISCUSSION: Despite few limitations, the methods described here are relevant to the development of sustainable pharmacovigilance systems for drugs used by pregnant women in the tropics using health and demographic surveillance sites to prospectively ascertain drug safety in early pregnancy. TRIAL REGISTRATION: NCT01232530.

Matèries

Malària, Embaràs, Agents antiinfecciosos, Medicina prenatal, Estudi de casos

Matèries (anglès)

Malaria, Pregnancy, Prenatal medicine, Case studies

Citació

Col·leccions

Articles publicats en revistes (ISGlobal)

Citació

TINTO, Halidou, SEVENE, Esperança júlia pires, DELLICOUR, Stephanie, CALIP, Gregory s., ALESSANDRO, Umberto d', MACETE, Eusebio víctor, NAKANABO-DIALLO, Seydou, KAZIENGA, Adama, VALÉA, Innocent, SORGHO, Hermann, VALA, Anifa, AUGUSTO, Orvalho, RUPÉREZ, María, MENÉNDEZ, Clara, OUMA, Peter, DESAI, Meghna, TER KUILE, Feiko o., STERGACHIS, Andy. Assessment of the safety of antimalarial drug use during early pregnancy (ASAP): protocol for a multicenter prospective cohort study in Burkina Faso, Kenya and Mozambique. _Reproductive Health_. 2015. Vol. 12, núm. 112, pàgs. 1-9. [consulta: 25 de desembre de 2025]. ISSN: 1742-4755. [Disponible a: https://hdl.handle.net/2445/69257]

Exportar metadades

JSON - METS

Compartir registre